Want to see BIOA full AI Analyst Report?
BIOA Stock Chart & Stats
$21.77
$0.56(2.57%)
At close: 4:00 PM EDT
$21.77
$0.56(2.57%)
Day’s Range― - ―
52-Week Range$4.38 - $25.96
Previous CloseN/A
Volume15.03K
Average Volume (3M)668.29K
Market Cap
$486.51M
Enterprise Value$783.09
Total Cash (Recent Filing)$318.75M
Total Debt (Recent Filing)$2.83M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Nov 05, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.38
Shares Outstanding45,896,908
10 Day Avg. Volume554,284
30 Day Avg. Volume668,290
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)1.75
Price to Sales (P/S)52.85
P/FCF Ratio-5.77
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$35.63Price Target Upside63.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.52
Revenue Forecast (FY)$7.60M
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrajectoryConsistent TTM revenue growth to $10.4M (~38% y/y) demonstrates early commercialization traction beyond preclinical activities. Durable top-line momentum helps de-risk the development profile, supports incremental investment in trials and commercial capabilities, and provides a foundation for future margin expansion.
Strong, Low-Leverage Balance SheetVery low leverage and sizable assets give BioAge meaningful financial flexibility versus many peers. This reduces near-term liquidity risk, supports self-funding of key trials or selective partnerships, and provides optionality to advance multiple programs without immediate distress from debt covenants.
Advanced NLRP3 Program And Clinical MomentumPhase‑1 validation and progression into Phase‑2 plus plans for a second proof‑of‑concept create durable platform potential. Demonstrated biomarker suppression and multisite indication planning expand the addressable market and increase the likelihood that clinical success in one area can catalyze further program investment or partnerships.
Bears Say
High Operating Cash BurnSustained operating outflows of roughly -$112M TTM indicate heavy cash consumption typical of clinical-stage biotech. This persistent burn will erode reserves absent financing or partnership, constraining strategic flexibility and raising the probability of capital raises that dilute existing shareholders.
Large Net Losses And Negative ProfitabilityA nearly -$95M TTM net loss shows the cost base far outpaces current revenue. Deep, sustained negative profitability limits the company's ability to self-fund growth, delays any path to positive margins, and increases vulnerability if clinical progress slows or requires additional investment.
Dependence On External Financing Or PartnershipsThe company’s cash burn and loss profile imply reliance on future financing or deals to sustain program advancement. That dependence can cause dilution, timing risk relative to clinical milestones, or pressure to accept less favorable partner economics, affecting long‑term shareholder value.
BioAge Labs, Inc. News
BIOA FAQ
What was BioAge Labs, Inc.’s price range in the past 12 months?
BioAge Labs, Inc. lowest stock price was $4.38 and its highest was $25.95 in the past 12 months.
What is BioAge Labs, Inc.’s market cap?
BioAge Labs, Inc.’s market cap is $486.51M.
When is BioAge Labs, Inc.’s upcoming earnings report date?
BioAge Labs, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 81 days.
How were BioAge Labs, Inc.’s earnings last quarter?
BioAge Labs, Inc. released its earnings results on Aug 05, 2026. The company reported -$0.58 earnings per share for the quarter, beating the consensus estimate of -$0.607 by $0.027.
Is BioAge Labs, Inc. overvalued?
According to Wall Street analysts BioAge Labs, Inc.’s price is currently Undervalued.
Does BioAge Labs, Inc. pay dividends?
BioAge Labs, Inc. does not currently pay dividends.
What is BioAge Labs, Inc.’s EPS estimate?
BioAge Labs, Inc.’s EPS estimate is -0.5.
How many shares outstanding does BioAge Labs, Inc. have?
BioAge Labs, Inc. has 45,896,908 shares outstanding.
What happened to BioAge Labs, Inc.’s price movement after its last earnings report?
BioAge Labs, Inc. reported an EPS of -$0.58 in its last earnings report, beating expectations of -$0.607. Following the earnings report the stock price went up 2.641%.
Which hedge fund is a major shareholder of BioAge Labs, Inc.?
Currently, no hedge funds are holding shares in BIOA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioAge Labs, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.63 (63.64% Upside)
$35.63 (63.64% Upside)
Blogger Sentiment
Bearish
BIOA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 26.3%
Last 30 Days ▲ 26.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
363.19%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.21%
Trailing 12-Months
Company Description
BioAge Labs, Inc.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
BIOA Stock 12 Month Forecast
Average Price Target
$35.63
▲(63.64% Upside)
Technical Analysis
Ironwood Pharma
―
Lifecore Biomedical
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
Incannex Healthcare Limited Sponsored ADR
―
Ownership Overview
9.25% Insiders
6.21% Mutual Funds
46.99% Other Institutional Investors
26.59% Public Companies and
Individual Investors